Optimizing the safety of antibody–drug conjugates for patients with solid tumours

Nature Reviews Clinical Oncology, Published online: 09 June 2023; doi:10.1038/s41571-023-00783-wAdvances in technology have enabled the development of several novel antibody–drug conjugates (ADCs) with encouraging clinical activity in patients with advanced-stage solid tumours. Indications for these therapies are expanding rapidly to earlier lines of therapy. Nonetheless, the toxicities of these various agents are not trivial and can be fatal, even in patients with early stage disease. In this Review, the authors summarize the toxicities of ADCs in patients with solid tumours both as monotherapies and in combination with other agents and discuss various ongoing research efforts attempting to optimize the therapeutic index of these agents.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research